Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...

Plants are very important living things. They have lots of jobs, such as providing animals with food and releasing oxygen into the air. To survive and carry out these jobs, they all need three ...

Figure 1. TNFSF and receptor-ligand complex formation. The structure of TNFSF (light purple) in its unbound state (left), followed by its binding to the TNFSF receptor (green, blue, and pink) (middle) ...

Endoscopic augmentation of the lower oesophageal sphincter using hydrogel implants for the treatment of gastro-oesophageal reflux disease IPG222 27 June 2007 27 June 2007 Carmustine implants and ...

Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures CG64 17 March 2008 8 July 2016 ...

Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC ...

Treatment and lifestyle change recommendations by cardiologist for patients attending cardiology outpatient clinics: a TLC study Advances in Interventional Cardiology 2025 ...